189 related articles for article (PubMed ID: 26750243)
1. A human monoclonal antibody against HPV16 recognizes an immunodominant and neutralizing epitope partially overlapping with that of H16.V5.
Xia L; Xian Y; Wang D; Chen Y; Huang X; Bi X; Yu H; Fu Z; Liu X; Li S; An Z; Luo W; Zhao Q; Xia N
Sci Rep; 2016 Jan; 6():19042. PubMed ID: 26750243
[TBL] [Abstract][Full Text] [Related]
2. Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity.
Zhao Q; Modis Y; High K; Towne V; Meng Y; Wang Y; Alexandroff J; Brown M; Carragher B; Potter CS; Abraham D; Wohlpart D; Kosinski M; Washabaugh MW; Sitrin RD
Virol J; 2012 Feb; 9():52. PubMed ID: 22356831
[TBL] [Abstract][Full Text] [Related]
3. High-Resolution Structure Analysis of Antibody V5 and U4 Conformational Epitopes on Human Papillomavirus 16.
Guan J; Bywaters SM; Brendle SA; Ashley RE; Makhov AM; Conway JF; Christensen ND; Hafenstein S
Viruses; 2017 Dec; 9(12):. PubMed ID: 29211035
[TBL] [Abstract][Full Text] [Related]
4. Epitope clustering analysis for vaccine-induced human antibodies in relationship to a panel of murine monoclonal antibodies against HPV16 viral capsid.
Zhang C; Huang X; Chen S; Li Y; Li Y; Wang X; Tang J; Xia L; Lin Z; Luo W; Li T; Li S; Zhang J; Xia N; Zhao Q
Vaccine; 2018 Oct; 36(45):6761-6771. PubMed ID: 30287156
[TBL] [Abstract][Full Text] [Related]
5. Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera.
Carter JJ; Wipf GC; Madeleine MM; Schwartz SM; Koutsky LA; Galloway DA
J Virol; 2006 May; 80(10):4664-72. PubMed ID: 16641259
[TBL] [Abstract][Full Text] [Related]
6. A cryo-electron microscopy study identifies the complete H16.V5 epitope and reveals global conformational changes initiated by binding of the neutralizing antibody fragment.
Lee H; Brendle SA; Bywaters SM; Guan J; Ashley RE; Yoder JD; Makhov AM; Conway JF; Christensen ND; Hafenstein S
J Virol; 2015 Jan; 89(2):1428-38. PubMed ID: 25392224
[TBL] [Abstract][Full Text] [Related]
7. In silico/In vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccine.
Namvar A; Bolhassani A; Javadi G; Noormohammadi Z
Sci Rep; 2019 Oct; 9(1):15225. PubMed ID: 31645650
[TBL] [Abstract][Full Text] [Related]
8. Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types.
Christensen ND; Cladel NM; Reed CA; Budgeon LR; Embers ME; Skulsky DM; McClements WL; Ludmerer SW; Jansen KU
Virology; 2001 Dec; 291(2):324-34. PubMed ID: 11878901
[TBL] [Abstract][Full Text] [Related]
9. Characterization of neutralizing epitopes within the major capsid protein of human papillomavirus type 33.
Roth SD; Sapp M; Streeck RE; Selinka HC
Virol J; 2006 Oct; 3():83. PubMed ID: 17014700
[TBL] [Abstract][Full Text] [Related]
10. Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles.
Ryding J; Dahlberg L; Wallen-Öhman M; Dillner J
J Gen Virol; 2007 Mar; 88(Pt 3):792-802. PubMed ID: 17325351
[TBL] [Abstract][Full Text] [Related]
11. Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing.
Tyler M; Tumban E; Dziduszko A; Ozbun MA; Peabody DS; Chackerian B
Vaccine; 2014 Jul; 32(34):4267-74. PubMed ID: 24962748
[TBL] [Abstract][Full Text] [Related]
12. A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11.
Slupetzky K; Gambhira R; Culp TD; Shafti-Keramat S; Schellenbacher C; Christensen ND; Roden RB; Kirnbauer R
Vaccine; 2007 Mar; 25(11):2001-10. PubMed ID: 17239496
[TBL] [Abstract][Full Text] [Related]
13. The U4 Antibody Epitope on Human Papillomavirus 16 Identified by Cryo-electron Microscopy.
Guan J; Bywaters SM; Brendle SA; Lee H; Ashley RE; Christensen ND; Hafenstein S
J Virol; 2015 Dec; 89(23):12108-17. PubMed ID: 26401038
[TBL] [Abstract][Full Text] [Related]
14. Structural comparison of four different antibodies interacting with human papillomavirus 16 and mechanisms of neutralization.
Guan J; Bywaters SM; Brendle SA; Lee H; Ashley RE; Makhov AM; Conway JF; Christensen ND; Hafenstein S
Virology; 2015 Sep; 483():253-63. PubMed ID: 25996608
[TBL] [Abstract][Full Text] [Related]
15. Mutations on the FG surface loop of human papillomavirus type 16 major capsid protein affect recognition by both type-specific neutralizing antibodies and cross-reactive antibodies.
Carpentier GS; Fleury MJ; Touzé A; Sadeyen JR; Tourne S; Sizaret PY; Coursaget P
J Med Virol; 2005 Dec; 77(4):558-65. PubMed ID: 16254978
[TBL] [Abstract][Full Text] [Related]
16. Development of a non-denaturing electrophoresis system for characterization of neutralizing epitopes on HPV virus-like particles.
Studentsov YY; Burk RD
J Virol Methods; 2007 Feb; 139(2):208-19. PubMed ID: 17137641
[TBL] [Abstract][Full Text] [Related]
17. Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.
Pouyanfard S; Spagnoli G; Bulli L; Balz K; Yang F; Odenwald C; Seitz H; Mariz FC; Bolchi A; Ottonello S; Müller M
J Virol; 2018 Feb; 92(4):. PubMed ID: 29212932
[TBL] [Abstract][Full Text] [Related]
18. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2.
Tumban E; Peabody J; Peabody DS; Chackerian B
PLoS One; 2011; 6(8):e23310. PubMed ID: 21858066
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a major neutralizing epitope on human papillomavirus type 16 L1.
White WI; Wilson SD; Palmer-Hill FJ; Woods RM; Ghim SJ; Hewitt LA; Goldman DM; Burke SJ; Jenson AB; Koenig S; Suzich JA
J Virol; 1999 Jun; 73(6):4882-9. PubMed ID: 10233949
[TBL] [Abstract][Full Text] [Related]
20. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
